Catalysis with engineered enzymes has provided more efficient routes for the production of active pharmaceutical agents. However, the potential of biocatalysis to assist in early-stage drug discovery campaigns remains largely untapped. In this study, we have developed a biocatalytic strategy for the construction of sp3-rich polycyclic compounds via the intramolecular cyclopropanation of benzothiophenes and related heterocycles. Two carbene transferases with complementary regioisomer selectivity were evolved to catalyse the stereoselective cyclization of benzothiophene substrates bearing diazo ester groups at the C2 or C3 position of the heterocycle. The detailed mechanisms of these reactions were elucidated by a combination of crystallographic and computational analyses. Leveraging these insights, the substrate scope of one of the biocatalysts could be expanded to include previously unreactive substrates, highlighting the value of integrating evolutionary and rational strategies to develop enzymes for new-to-nature transformations. The molecular scaffolds accessed here feature a combination of three-dimensional and stereochemical complexity with ‘rule-of-three’ properties, which should make them highly valuable for fragment-based drug discovery campaigns.
This work results from the collaboration between the groups of in collaboration with Prof. Rudi Fasan (now at the University of Texas, USA), the group of Prof. K.N. Houk (UCLA, USA), and Dr. Marc Garcia-Borràs.
It has been recently published in Nature Chemistry:
D. A. Vargas, X. Ren, A. Sengupta, L. Zhu, S. Roy, M. Garcia-Borràs, K. N. Houk* & R. Fasan*.
“Biocatalytic strategy for the construction of sp3-rich polycyclic compounds from directed evolution and computational modelling”
Nat. Chem., 2024, in press.
DOI: 10.1038/s41557-023-01435-3
Girona, March 4th, 2024
For more info: ges.iqcc@udg.edu